mProX™ Human FCGR3B Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

FCGR3B, also known as Fc-gamma receptor III-B, has been studied in various research areas. In the field of lung squamous cell carcinoma (LUSC), FCGR3B was identified as one of the hub-targeted mRNAs in the miRNA-mRNA regulatory network. It showed interactions with other targeted mRNAs and provided insights into the molecular pathogenesis of LUSC. In the context of gene copy number estimation, FCGR3B was used as a validation marker for the computational method GeneToCN. The method accurately predicted copy numbers for FCGR3A, but showed reduced accuracy for FCGR3B. In multiple myeloma, FCGR3B was identified as one of the protective proteins causally associated with MM risk. It was inversely associated with MM and showed potential as a therapeutic target. In head and neck squamous cell carcinoma (HNSCC), FCGR3B was identified as one of the new markers associated with the tumor microenvironment (TME). It was used in the construction of a risk model to predict the prognosis of HNSCC patients. Finally, in dermatomyositis, FCGR3B was identified as a potential drug target based on genomic variation associated with the disease. Overall, FCGR3B has been implicated in cancer prognosis, gene copy number estimation, immune response, and drug repositioning.